← feed

Is NCT02138812 results overdue?

Yes — results are overdue. Primary completion was 2017-04-28; the FDAAA-801 reporting deadline (2018-04-28) passed 2976 days ago and no results are posted on ClinicalTrials.gov.

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

NCT IDNCT02138812 ↗
SponsorBayer (INDUSTRY)
PhasePHASE1
StatusTERMINATED
Primary completion2017-04-28 (ACTUAL)
Reporting deadline2018-04-28 (completion + 365d)
Days overdue2976
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 70064ded3dfb4a82… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02138812. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →